BioTuesdays

Category - Markets

Markets

BTIG ups Eidos Therapeutics PT to $56 from $38

BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to...

September 13, 2019
T2 Biosystems Logo
Markets

Analysts up T2 Biosystems price targets

Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...

September 12, 2019
AVEO Pharmaceuticals Logo
Markets

HCW ups AVEO Pharma to buy; PT to $1.75 from $1

H.C. Wainwright upgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “buy” from “neutral” and raised its price target to $1.75 from $1, citing a positive overall survival (OS) update from the Phase 3 TIVO-3 study of tivozanib...

September 11, 2019
Mallinckrodt
Markets

SVB Leerink cuts Mallinckrodt PT to $2 from $7

SVB Leerink reduced its price target for “market perform” rated Mallinckrodt (NYSE:MNK) to $2 from $7, reflecting a higher risk profile for the company. The stock closed at $1.59 on Sept. 5. “While we believe that the...

September 6, 2019
Markets

HCW starts Corcept Therapeutics at buy; PT $18

H.C. Wainwright launched coverage of Corcept Therapeutics (NASDAQ:CORT) with a “buy” rating and $18 price target. The stock closed at $12.59 on Sept. 5. Corcept is focused on development and commercialization of...

September 6, 2019
Stereotaxis
Markets

Stereotaxis to uplist to NYSE American

The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on...

September 5, 2019